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 Experimental autoimmune encephalomyelitis 
(EAE) is a CD4 + T cell – driven autoimmune 
disease that shares clinical and histological simi-
larities with multiple sclerosis (MS). In EAE, 
CD4 + T cells specifi c for antigens expressed in 
central nervous system (CNS) myelin initiate a 
localized infl ammatory process that results in 
demyelination, axonal transection, and clinical 
defi cits. Active EAE and MS lesions are charac-
terized by perivascular infi ltrates predominantly 
composed of myeloid cells (macrophages, den-
dritic cells, and activated microglia) and lym-
phocytes ( 1, 2 ). Consequently, a large body of 
research has focused on the role of ML chemo-
kines (particularly CCL1, CCL2, CCL3, and 
CCL5) and ELR    CXC chemokines (such as 
CXCL10) in the recruitment of circulating lym-
phocytes and monocytes to the CNS during 
EAE and MS ( 3, 4 ). 
 ELR + CXC chemokines, such as CXCL1 
and CXCL2 in mice and CXCL8 in humans, 
are also up-regulated in EAE lesions (where they 
localize to astrocytes and, to some extent, mi-
croglia) and in the peripheral blood mononu-
clear cells and cerebrospinal fl uid of MS patients 
( 5 – 10 ). These chemokines are potent attractants 
for PMN. Hence, in mouse models of pulmo-
nary aspergillosis (toxoplasmosis and staphylo-
coccal cerebritis), expression of CXCR2, a major 
receptor for ELR + CXC chemokines in mice, 
is critical for the accumulation of PMN at sites 
of infl ammation and, consequently, eradication 
of microbial pathogens ( 11 – 13 ). Furthermore, 
blockade of CXCR2 prevents infl ammation 
and tissue destruction in experimental models 
of arthritis and CD4 + T cell – mediated hyper-
sensitivity reactions in the lungs, both of which 
entail PMN-rich infl ammatory infi ltrates in the 
target organ ( 14, 15 ). In addition, under certain 
conditions ELR + CXC chemokines mediate 
monocyte arrest. For example, they play a criti-
cal role in monocyte infi ltration in atheroscle-
rotic plaques ( 16 ). 
 Relatively little is known about the bio-
logical signifi cance or cellular target of ELR + 
CXC chemokines in the development and/or 
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 The ELR + CXC chemokines CXCL1 and CXCL2 are up-regulated in the central nervous 
system (CNS) during multiple sclerosis (MS) and its animal model, experimental auto-
immune encephalomyelitis (EAE). However, their functional signifi cance and the pathways 
regulating their expression are largely unknown. We show that transfer of encephalitogenic 
CD4 + Th17 cells is suffi cient to induce CXCL1 and CXCL2 transcription in the spinal cords 
of naive, syngeneic recipients. Blockade or genetic silencing of CXCR2, a major receptor for 
these chemokines in mice, abrogates blood – brain barrier (BBB) breakdown, CNS infi ltration 
by leukocytes, and the development of clinical defi cits during the presentation as well as 
relapses of EAE. Depletion of circulating polymorphonuclear leukocytes (PMN) had a similar 
therapeutic effect. Furthermore, injection of CXCR2 + PMN into CXCR2   /   mice was suffi -
cient to restore susceptibility to EAE. Our fi ndings reveal that a Th17 – ELR + CXC chemokine 
pathway is critical for granulocyte mobilization, BBB compromise, and the clinical manifes-
tation of autoimmune demyelination in myelin peptide – sensitized mice, and suggest new 
therapeutic targets for diseases such as MS. 
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the course. IL-10 was not elevated to a statistically signifi cant 
extent at any stage. Expression of every chemokine and cyto-
kine in our panel remained at baseline levels across multiple 
time points in spinal cords of mice immunized with an immuno-
dominant epitope of infl uenza nucleoprotein (NP 260-283 ). 
 As mentioned earlier, PMN have been detected crossing 
the blood – brain barrier (BBB) during the preclinical stage of 
EAE, when infl ammatory infi ltrates are beginning to form but 
before the manifestation of neurological defi cits ( 17 ). There-
fore, we measured CNS CXCL1 and CXCL2 on a daily basis 
starting on day 3 after immunization with PLP 139-151 . Tran-
scripts encoding CXCL1 and CXCL2, as well as CXCR2 
and PGRP, were detectable above baseline levels as early as 
4 d before the expected day of clinical onset and increased 
progressively thereafter ( Fig. 1 B ). CD4, IL-17, and IFN-  
mRNA followed a similar pattern. In contrast, transcripts en-
coding CCL2, CCL3, CCL5, and CCL19 rose above baseline 
at later time points than the ELR + CXC chemokines, sug-
gesting that PMN may be actively recruited to the spinal cord 
before most other infl ammatory cells. IL-10 was transcribed at 
a low level that did not change during the course of disease. 
 Transfer of purifi ed myelin-reactive CD4 + Th17 cells 
is suffi cient to induce CXCL1 and CXCL2 expression 
in the CNS 
 Th17 cells have recently been implicated in the pathogenesis 
of EAE and MS, as well as other organ-specifi c autoimmune 
diseases ( 19 – 21 ). IL-17 stimulates ELR + CXC chemokine 
production in multiple cell types. Therefore we questioned 
whether transfer of myelin-specifi c CD4 Th17 cells would 
be suffi  cient to induce CXCL1 and CXCL2 transcription in 
the spinal cords of naive, syngeneic hosts. Purifi ed CD4 + T 
cells, from donor SJL mice primed with PLP 139-151 in IFA, 
were challenged with antigen for 96 h in the presence of 
recombinant IL-23, IL-12, or a neutralizing antibody against 
the IL-12/IL-23 p40 chain before injection into previously 
un manipulated syngeneic hosts. PLP-reactive T cells prolif-
erated in a similar fashion ( Fig. 2 A , right) and expanded 
to a similar extent (based on yields of viable lymphoblasts; 
not depicted) under each set of culture conditions in vitro. 
As expected, IL-23 – stimulated cells secreted large quanti-
ties of IL-17, whereas IL-12 – stimulated cells secreted large 
quantities of IFN-  during antigenic challenge in vitro ( Fig. 
2 A , left). Cells cultured with anti-p40 produced neither of 
those cytokines to detectable levels. IL-23 – stimulated cells 
preferentially induced expression of IL-17 mRNA in spinal 
cords of adoptive transfer recipients ( Fig. 2 B ). In contrast, 
IL-12 – stimulated cells induced CNS up-regulation of IFN-  
but not IL-17. 
 Spinal cords from mice injected with IL-23 – driven Th17 
cells expressed dramatically elevated levels of CXCL1 and 
CXCL2, as well as PGRP (a neutrophil-specifi c marker) and 
G-CSF, compared with cords from naive mice ( Fig. 2 B 
and not depicted). In contrast, those molecules remained at 
background levels in spinal cords from mice injected with 
PLP-reactive CD4 + T cells that had been reactivated in the 
maintenance of autoimmune demyelinating disease, in which 
infi ltrates are dominated by lymphocytes and monocytes. 
Although PMN have been detected entering the CNS dur-
ing the preclinical phase of EAE ( 17 ), their relative paucity in 
mature EAE and MS lesions has led some investigators to 
question their importance ( 8 ). With regard to more populous 
myeloid subsets in EAE and MS lesions, activated macro-
phages are recruited to the CNS by a CCL2-dependent 
pathway across several EAE models ( 18 ). Perhaps because of 
such observations, the role of ELR + CXC chemokines in the 
pathophysiology of autoimmune demyelination has not been 
previously investigated in depth. However, a growing body of 
data indicates that they merit attention. For example, IL-17, 
a potent inducer of ELR + CXC chemokines, was recently 
implicated in the pathogenesis of both EAE and MS ( 19 – 21 ). 
In addition, McColl et al. found that in vivo depletion of 
PMN prevents acute EAE induced either by active immuni-
zation or adoptive transfer ( 22 ). Interestingly, PMN com-
prise a signifi cant percentage of CNS-infi ltrating leukocytes 
in an atypical and severe form of EAE manifested by IFN-  
and IFN-  receptor knockout mice, as well as in aggressive 
forms of human infl ammatory demyelinating disease, such as 
Marburg ’ s variant of MS and hemorrhagic leukoencephalitis, 
suggesting that these cells might directly promote CNS in-
fl ammation and/or white matter injury ( 9, 23, 24 ). Collec-
tively, these fi ndings led us to comprehensively examine for 
the fi rst time the role of CXCR2 and ELR + CXC chemo-
kines in conventional EAE models, to investigate the rela-
tionship between TH17 cell infi ltration and ELR + CXC 
chemokine expression in the CNS, and to specifi cally address 
whether PMN activation/recruitment via ELR + CXC che-
mokine pathways is necessary for the development of relapses 
after clinical onset. 
 RESULTS 
 CNS expression of ELR + CXC chemokines and CXCR2 mirrors 
clinical disease activity during relapsing-remitting EAE 
 To determine the pattern of ELR + CXC chemokine ex-
pression throughout the course of relapsing-remitting disease, 
we immunized SJL mice with an immunodominant epitope of 
proteolipid protein (PLP 139-151 ) in CFA and measured CNS 
expression of CXCL1 and CXCL2 mRNA in samples grouped 
according to clinical stage. In agreement with earlier reports 
( 5 – 8 ), we found that CNS CXCL1 and CXCL2 were up-
regulated from baseline levels (as measured in spinal cords from 
naive mice) at the peak of clinical EAE ( Fig. 1 A ). Expression 
of both chemokines fell to baseline during the subsequent 
remission and rebounded during relapse. Peptidoglycan rec-
ognition protein (PGRP), a PMN-specifi c marker ( 25 ), and 
CXCR2, an ELR + CXC chemokine receptor expressed pre-
dominantly by PMN, exhibited similar kinetics. The same was 
true of the proinfl ammatory T cell eff ector cytokines IL-17 
and IFN-  and the ML chemokine CCL2. In contrast, CCL19 
transcripts were elevated during the initial episode but pro-
gressively fell with each successive stage, whereas CCL3 and 
CCL5 transcripts were stable at a heightened level throughout 
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cells secreted IFN-  in an antigen-specifi c manner, suggest-
ing that the donor cells maintained their Th phenotypes after 
adoptive transfer (unpublished data). 
 CXCR2 blockade abrogates EAE 
 To assess the physiological signifi cance of ELR + CXC che-
mokine expression in our model, we injected SJL mice with 
either anti-CXCR2 antiserum or normal rabbit serum (NRS) 
between days 8 and 14 after immunization with PLP 135-151 ( 13 ). 
presence of anti – IL-12 p40. By comparison to the Th17 
eff ectors, IL-12 – driven Th1 cells were relatively ineffi  cient at 
inducing ELR + CXC chemokines in the CNS. Of note, 
PLP-specifi c donor T cells from each set of cultures survived/
expanded to a comparable extent in the peripheral lymphoid 
organs of host mice, as assessed by lymphoproliferative recall 
responses on day 14 after transfer (unpublished data). Spleno-
cytes harvested from recipients of IL-23 – polarized cells se-
creted IL-17 and splenocytes from recipients of IL-12 – polarized 
 Figure 1.  ELR + CXC chemokines are up-regulated in the CNS during preclinical and active stages of EAE. (A) SJL mice were immunized with PLP 139-151 
or NP 260-283 (control) in CFA. Spinal cord RNA was isolated from PLP 139-151 – primed mice during distinct stages of EAE, or from NP 260-283 – primed mice at 
analogous time points after immunization, for real-time RT-PCR analysis. Data represent fold induction compared with naive spinal cords ( n = 4 mice per group). 
(B) RNA was extracted from spinal cords between days 8 and 12 after immunization with PLP 139-151 or NP 260-283 for analysis by real-time RT-PCR ( n = 5 mice 
per group). *, P  < 0.05 for PLP-immunized mice compared with NP-immunized mice. n.s., not signifi cantly different from naive spinal cords. 
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published data). Collectively these data suggest that the 
therapeutic eff ect of anti-CXCR2 may be secondary to 
blockade of PMN mobilization from the bone marrow 
into the blood stream. 
 Experiments using CXCR2   /   ( 26 ) mice corroborated 
our fi ndings with the CXCR2-neutralizing antiserum. In re-
peated experiments, 90 – 100% of myelin antigen – primed WT 
mice developed EAE (mean clinical score = 2 – 3), signifying 
conspicuous hind-limb paresis ( Fig. 3 G ). In contrast, none of 
the CXCR2   /   mice on the same genetic background that 
were subjected to the same immunization protocol acquired 
neurological defi cits. CXCR2 +/   mice exhibited an inter-
mediate phenotype. 
 PMN are mobilized from the bone marrow and accumulate 
in the CNS during preclinical and acute stages of EAE 
 To monitor the migration of PMN during the development 
of EAE, we tracked Ly6G + , 7/4 + , MHC class II    cells in 
the circulatory and CNS compartments by fl ow cytometry. 
PMN began accumulating in the blood during the preclinical 
phase, and their percentage among circulating leukocytes 
rose through peak disease ( Fig. 4, A and B ). Similarly, PMN 
appeared in the CNS shortly before the expected day of clin-
ical onset, and their absolute numbers increased in propor-
tion to the growing infl ammatory infi ltrate ( Fig. 4, C and D ). 
Anti-CXCR2 treatment signifi cantly reduced mean clinical 
EAE scores ( Fig. 3 A ). Mice that were asymptomatic during 
treatment with anti-CXCR2 developed EAE within 2 – 3 d of 
the last injection of antiserum, in agreement with the onset 
of relapse in the control group. Of greater clinical relevance, 
administration of anti-CXCR2 during remission completely 
suppressed subsequent relapse ( Fig. 3 B ). 
 Anti-CXCR2 treatment prevented BBB breakdown, the 
development of infl ammatory infi ltrates, and up-regulation 
of proinfl ammatory cytokines (IL-17, IL-6, and IFN-  ) in 
the CNS of the protected mice ( Fig. 3, C – E ). PGRP mRNA 
did not rise above background levels, indicating that PMN 
had failed to enter the CNS. In contrast, CD4 + T cells iso-
lated from lymph nodes and spleens of anti-CXCR2 – treated 
mice mounted robust myelin-specifi c proliferative responses 
upon in vitro challenge ( Fig. 3 F ). Hence, our data indicate 
that CXCR2 – PMN – dependent pathways are necessary for 
the clinical and histopathological manifestation of EAE de-
spite the presence of activated myelin-specifi c T cells in the 
peripheral lymphoid organs. 
 Administration of anti-CXCR2 in vivo had no eff ect 
on the percentage or absolute number of bone marrow 
PMN in multiple experiments; its eff ect on circulating 
PMN was more variable. Anti-CXCR2 does not facilitate 
complement-mediated lysis of neutrophils in vitro (un-
 Figure 2.  Transfer of myelin-reactive Th17 cells induces CNS expression of CXCL1 and CXCL2. LN cells from donor SJL mice immunized with 
PLP 139-151 in IFA were cultured with antigen in the presence of either recombinant IL-23 (for the generation of Th17 cells), IL-12 (for the generation of Th1 
cells), or anti – IL-12/23 p40 neutralizing antibody (for the generation of lineage-uncommitted cells). (A, left and middle) Supernatants were collected seri-
ally and subjected to ELISA for measurement of IL-17 and IFN-  levels. (A, right) Some wells were pulsed with tritiated thymidine at 72 h and harvested 
12 h later for measurement of radioisotope incorporation. Data represent mean  ± SD. (B) Spinal cords were harvested from hosts that had been injected 
with either Th17, Th1, or uncommitted PLP 139-151 – reactive T cells 10 d earlier ( n = 5 mice per group). RNA was extracted for analysis by real-time RT-PCR. 
The results show mean relative expression of the specifi ed transcripts in cords from host mice to cords from naive mice. A representative experiment of 
four is shown. *, P  < 0.05 compared with naive mice. 
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However, 2 – 3 d after the cessation of injections, in agreement 
with recovery of the circulating PMN pool, we consistently 
observed an acute increase in cerebrovascular permeability 
and the onset of hind-limb weakness. Furthermore, initiation 
of RB6 treatments during remission prevented subsequent 
cerebrovascular compromise and clinical relapse ( Fig. 5, 
D and E ). Histological studies corroborated our clinical fi nd-
ings, demonstrating that RB6 treatment completely inhibited 
CNS infl ammation in PLP-immunized mice ( Fig. 5, F and G ). 
Therefore, PMN depletion by RB6 had similar eff ects to ELR + 
CXC chemokine blockade by anti-CXCR2 in maintaining 
the integrity of the BBB and preventing the clinical and his-
tological manifestations of EAE. 
 PMN depletion does not alter peripheral myelin-specifi c 
T cell responses 
 PMN can directly trigger dendritic cell maturation via inter-
actions between Mac-1 and DC-SIGN, thereby boosting 
Histological analysis confi rmed the presence of PMN, based 
on morphological characteristics, within small perivascular and 
meningeal infi ltrates during the preclinical phase and within 
mature perivascular and parenchymal infi ltrates in mice with 
neurological defi cits ( Fig. 4 E ). 
 PMN depletion prevents the initiation and relapse of EAE 
 To defi nitively assess the functional relevance of PMN during 
diff erent stages of relapsing-remitting EAE, we injected PLP-
immunized mice with RB6 (an mAb specifi c for the myeloid 
marker Gr-1 that has been widely used to deplete PMN in vivo 
[ 27 ]) according to a variety of dosing schedules. We found 
that RB6 depleted circulating PMN without aff ecting other 
leukocyte subsets ( Fig. 5 A ; and Fig. S1, available at http://
www.jem.org/cgi/content/full/jem.20072404/DC1). 
 Injection of RB6 beginning at preclinical time points pre-
vented BBB breakdown and the development of neurological 
defi cits throughout the duration of treatment ( Fig. 5, B and C ). 
 Figure 3.  CXCR2 plays a critical role in the presentation and relapse of EAE. Mice immunized with PLP 139-151 in CFA were treated with anti-CXCR2 
antiserum or NRS between days 8 and 14 (A and C – E) or days 18 and 24 (B) after immunization. (A and B) Mice were rated for clinical signs of EAE on a daily 
basis. (C) BBB integrity was assessed on day 14 after immunization by Evans blue dye extravasation. Relative permeability is calculated as follows: ( μ g Evans 
blue/g spinal cord)/(  μ g Evans blue/g kidney). Data represent mean  ± SD. *, P  < 0.05 compared with naive mice. (D) Spinal cords were fi xed on day 14 after im-
munization. Representative hematoxylin and eosin sections are shown from fi ve mice per group. Bars: (left and right) 200  μ m; (middle) 50  μ m. (E) Spinal cords 
were sampled at the time of peak disease in the group injected with NRS and analyzed by real-time RT-PCR. Data represent fold induction relative to naive 
spinal cords (NRS,  n = 4; anti-CXCR2,  n = 3). *, P  < 0.05 for anti-CXCR2 – compared with NRS-treated mice. (F) CD4 + T cells, purifi ed from draining lymph nodes 
on day 14 after immunization, were stimulated with naive T cell – depleted splenocytes and 25  μ g/ml PLP 139-151 in vitro. Lymphoproliferation was measured by 
uptake of [ 3 H]thymidine. Data represent mean  ± SD. (G) BALB/c CXCR2 +/+ , CXCR2 +/   , and CXCR2   /   mice were immunized with PLP 185-206 in CFA to induce EAE. 
The mean daily clinical score of each group is shown (+/+,  n = 5; +/  ,  n = 8;   /  ,  n = 7). The experiment was repeated fi ve times with similar results. 
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ated during the eff ector stage, at a point after the generation of 
encephalitogenic CD4 + T cells in secondary lymphoid organs, 
and correlate with inhibition of PMN traffi  cking to the CNS. 
 Resistance of CXCR2   /   mice is overcome by transfer 
of CXCR2 +/+ PMN 
 Although ELR + CXC chemokines are most widely character-
ized as attractants and activators of PMN, they can also mediate 
monocyte arrest ( 16 ). To determine whether CXCR2 expres-
sion on PMN is suffi  cient for EAE susceptibility, we injected 
CXCR2   /   mice with purifi ed WT PMN over several days 
after immunization with PLP peptide. 100% of CXCR2   /   
mice treated in this manner succumbed to clinical and histo-
logical EAE, although at a lower severity in comparison to 
T cell proliferation and Th1 polarization ( 28 ). PMN also secrete 
cytokines and chemokines that can directly modulate T cell 
diff erentiation ( 29, 30 ). Therefore we investigated the eff ects 
of PMN depletion on the priming of myelin-specifi c T cells in 
the periphery. CD4 + T cells purifi ed from the lymph nodes of 
PLP-immunized mice that had been injected either with RB6 
or control antibodies mounted comparable lymphoprolifera-
tive and cytokine recall responses ( Fig. 6, A and B ). In contrast, 
RB6-treated mice failed to up-regulate IL-17, IFN-  , or IL-6 
in the CNS to the levels expressed in control mice at peak dis-
ease ( Fig. 6 C ). RB6 treatment also blocked CNS expression 
of PGRP, indicating that there was no detectable infi ltration 
by PMN. Hence, reminiscent of our fi ndings with the anti-
CXCR2 antiserum, the therapeutic actions of RB6 are medi-
 Figure 4.  PMN accumulate in the blood and infi ltrate the CNS during preclinical and active phases of EAE. (A and B) PBLs were analyzed by 
fl ow cytometry to determine the percentage of PMN (identifi ed as Ly6G + , 7/4 + , MHC class II    cells). (A) Representative FACS profi les. (B) Percentages of 
PMN among PBLs were averaged over four mice per group. *, P  < 0.001 compared with naive mice. (C and D) Spinal cord – infi ltrating cells were isolated 
and pooled from PLP 139-151 – immunized SJL mice ( n = 10 – 20) immediately before, or on the day of, clinical EAE onset. Cells from mice immunized with 
NP 260-183 served as controls. PMN were identifi ed by FACS analysis as in A. (C) Representative FACS profi les gated on MHC class II    cells. (D) Total number 
of cells per cord and the percentage of CNS-infi ltrating PMN. Data represent mean  ± SD of four independent experiments. *, P  < 0.05 compared with 
control. (E) Histological sections of spinal cords from PLP 139-151 – and NP 260-283 – immunized mice were Giemsa stained. PMN (arrows) are identifi ed by their 
characteristic nuclear morphology (insets). The sections shown are representative of four mice per group. All experiments were repeated three or more 
times with consistent results. Bars, 50  μ m. 
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development of EAE. This is an unexpected fi nding in light 
of the current dogma regarding the immunopathogenesis 
of autoimmune demyelinating disease. Researchers study-
ing EAE and other organ-specifi c autoimmune diseases have 
focused on the autoreactive T and/or B cells that guide path-
ological infl ammation. Macrophages and, more recently, den-
dritic cells, have also received attention because of their role 
in presenting myelin antigens and in infl icting damage to the 
target organ ( 1, 31 ). Consequently, research involving che-
mokines in EAE has focused on the ML and ELR    CXC 
chemokines that serve as the main chemoattractants for mono-
cytes and lymphocytes ( 3, 4 ). 
 Although PMN are among the fi rst leukocytes to infi l-
trate the CNS in some models of EAE ( 17 ), they are scarce in 
mature infi ltrates. Hence, PMN have not generally been pos-
ited as key eff ector cells in popular theories on the pathogen-
esis of EAE or relapsing-remitting MS. Nonetheless, previous 
PLP-immunized WT mice ( Fig. 7 and  Table I ). CXCR2   /   
mice injected with WT macrophages according to the same 
schedule remained resistant to EAE induction. PMN transfer 
induced BBB breakdown and CNS expression of IFN-  and 
IL-6 in primed CXCR2   /   hosts, whereas macrophage trans-
fer failed to do so ( Fig. 8, A and B ; and not depicted). Impor-
tantly, transfer of WT PMN resulted in CNS expression of 
PGRP and CXCR2, demonstrating that donor PMN homed 
to the target organ during the infl ammatory process. Antigen-
specifi c proliferation and cytokine secretion of lymph node 
CD4 + T cells was comparable between PLP-primed WT and 
CXCR2   /   mice, as well as CXCR2   /   mice that received 
WT PMN transfers ( Fig. 8, C and D ). 
 DISCUSSION 
 The current study demonstrates that ELR + CXC chemo-
kines and CXCR2-expressing PMN are required for the 
 Figure 5.  PMN depletion prevents BBB disruption and clinical and histopathological manifestations of EAE. SJL mice were injected with either 
RB6 or control IgG (0.5 mg per dose) every other day from days 8 – 16 (A – C, F, and G) or days 21 – 27 (D and E) after immunization with PLP 139-151 in CFA. 
(A) PBLs were collected at serial time points and analyzed by fl ow cytometry. PMN were identifi ed as CD11b + , 7/4 + , MHC class II    cells. The percentage of 
PMN was averaged over six mice per group. A representative FACS profi le of each group is shown. Data represent mean  ± SD. (B) Daily clinical scores 
were averaged over six mice in each group. (C) BBB integrity was assessed during the indicated stages of EAE in the control IgG – treated group by Evans 
blue dye extravasation. Data represent mean  ± SD of six mice per group. *, P  < 0.05 compared with naive mice. (D) The mean daily clinical score of each 
group ( n = 8) is shown. (E) BBB integrity was assessed during the time of relapse in the control IgG – treated group. Data represent mean  ± SD of six mice 
per group. *, P  < 0.05 compared with naive mice. (F and G) Spinal cords were harvested and fi xed on day 14 after immunization with PLP 139-151 . Sections 
were Giemsa stained to visualize cell morphology. Images are representative of sections from four mice per group. All experiments were repeated three or 
more times with consistent results. Bars: (F, left; and G) 200  μ m; (F, right) 50  μ m. 
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animal models of neuroinfl ammation ( 10, 34 ). Conversely, 
administration of recombinant G-CSF was associated with 
acute relapses when given to MS patients undergoing bone 
marrow transplantation ( 35 ). Most strikingly, PMN deple-
tion was recently reported to attenuate EAE induced either 
by active immunization or adoptive transfer ( 22 ). These ob-
servations are consistent with the results of our current study, 
which indicate that PMN-mobilizing and -activating factors 
play a critical role in facilitating autoimmune-mediated neuro-
infl ammation and demyelination. 
 The mechanism of action of PMN in EAE remains to be 
elucidated. PMN produce chemokines and cytokines and 
participate in cell-to-cell interactions with dendritic cells that 
could modulate the diff erentiation and/or activation of lym-
phocytes and monocytes ( 28 – 30 ). However, our data indi-
cate that PMN exert their functions during the eff ector rather 
than the induction phase of EAE because myelin-specifi c 
T cell expansion and Th1/Th17 diff erentiation were not 
impaired in either RB6-treated or CXCR2-defi cient mice 
( Fig. 6, A and B ; and  Fig. 8, C and D ). Furthermore, mice 
that were protected from EAE, either by anti-CXCR2 in-
jection or PMN depletion, experienced exacerbations within 
days of treatment withdrawal ( Fig. 3 A and  Fig. 5 B ). This 
indicates that encephalitogenic T cells had been generated 
in the periphery and were able to mediate disease as soon 
as functional PMN were available for collaboration. We and 
others ( 22 ) have found that PMN depletion suppresses EAE 
induced by the transfer of ordinarily encephalitogenic mye-
lin-specifi c T cells (unpublished data). The ability of PMN to 
facilitate the traffi  cking and/or eff ector functions of memory 
T cells is not confi ned to autoimmune disease. Hence, CXCL1-
dependent recruitment of PMN to cutaneous antigen challenge 
sites is required for the elicitation of contact hypersensitiv-
ity by previously primed, hapten-specifi c CD4 + and CD8 + 
T cells ( 36 ). 
 We postulate that PMN mediate or augment BBB break-
down during the period between the reactivation of mye-
lin-specifi c T cells in the CNS and the massive infl ux of 
nonspecifi c leukocytes that heralds the onset of clinical EAE. 
In support of our hypothesis, PMN were recently shown to 
be important for increased vascular permeability and clinical 
disease in the K/BxN serum transfer model of arthritis ( 37 ). 
Furthermore, increased cerebrovascular permeability occurs 
in association with PMN infi ltration of the CNS provoked 
by viral encephalitis, intracerebral injection of IL-1  or 
CXCL2, or by transgenic expression of CXCL1 in oligoden-
drocytes ( 38 – 42 ). In the case of the viral encephalitis and 
IL-1  injection models, depletion of PMN or neutralization 
of CXCL1 prevented compromise of the cerebrovasculature. 
Activated PMN can disrupt adherens junctions between endo-
thelial cells via contact (  2 integrin)-dependent pathways and 
via secretion of factors that trigger endothelial cell contrac-
tion (azurocidin and hydrogen peroxide), up-regulation of 
adhesion molecules (TNF and glutamate), and extracellular 
matrix degradation (elastase and other proteases) ( 43 – 47 ). In 
addition, the culture of activated PMN with brain endothelial 
publications have demonstrated that ELR + CXC chemo-
kines, as well as other PMN-related factors such as leukotri-
enes and G-CSF, are up-regulated in the CNS during EAE 
and MS ( 6 – 8, 32, 33 ). CXCL8 was found to be elevated in 
the sera and peripheral blood mononuclear cells from MS pa-
tients in comparison to healthy volunteers ( 10 ). Furthermore, 
recombinant IFN-  , used in the clinical setting to suppress 
MS relapses, reduces CXCL8 expression in MS and inhibits 
both PMN infi ltration of the CNS and BBB breakdown in 
 Figure 6.  PLP-specifi c peripheral CD4 + responses are not altered 
by PMN depletion, but CNS up-regulation of infl ammatory markers 
is blocked. (A and B) CD4 + T cells were isolated from draining lymph 
nodes of PLP-immunized SJL mice that had been treated with either con-
trol IgG (closed bars and squares) or RB6 (open bars and circles). The 
purifi ed T cells were cultured with naive T cell – depleted splenocytes with 
or without 25  μ g/ml PLP 139151 for ELISPOT (A) and [ 3 H]thymidine uptake 
proliferation (B) assays. The ELISPOT data shown were generated by sub-
tracting background spots (10 or fewer) that appeared in the absence of 
antigenic challenge. Data represent mean  ± SD. (C) Spinal cords from 
PLP-immunized mice that had been treated with either control IgG or 
RB6 were analyzed by real-time RT-PCR. Data represent fold induction 
relative to naive spinal cords ( n = 5 mice per group). *, P  < 0.05 for IgG- 
compared with RB6-treated mice. 
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function require cell-to-cell adherence but not transendothelial 
migration ( 50 ). This observation suggests that adhesion of 
PMN to the cerebrovascular wall alone might be suffi  cient to 
increase its permeability in vivo. If so, the seemingly paradoxical 
proposition that PMN are mechanistically involved in EAE 
despite composing a minor percentage of CNS-infi ltrating 
cells would be reconciled. 
 Resistance of CXCR2   /   mice to EAE is reversed by the 
transfer of WT PMN ( Table I ,  Fig. 7 , and  Fig. 8 ), indicating 
that ELR + CXC chemokines drive PMN-dependent events that 
are crucial for the development of clinical disease. The fact 
that CXCR2   /   mice supplemented with WT PMN expe-
rienced milder disease than WT littermates raises the possibil-
ity that expression of CXCR2 on cells other than PMN 
might also be important in this model of EAE. Nonetheless, 
our observation that PMN depletion and CXCR2 blockade 
have virtually identical eff ects on the clinical and histopatho-
logical features of EAE indicate that the ELR + CXC chemo-
kine pathway induces the activation and/or migration of 
PMN in a nonredundant fashion. These results contrast with 
those of Abromson-Leeman et al., who reported that three 
out of four myelin-specifi c T cell lines successfully transferred 
EAE to naive CXCR2   /   mice ( 51 ). However, it is not clear 
that in vitro – derived T cell lines mimic the biological properties 
of endogenous pools of myelin-specifi c T cells activated in vivo. 
cells triggers degradation of the adherens junction molecule 
  -catenin ( 48 ), and intracerebral injection of the PMN gran-
ule proteins neutrophil elastase and cathepsin G leads to BBB 
disruption ( 49 ). 
 Although we cannot conclude defi nitively that CXCR2 + 
PMN act in such a fashion during EAE on the basis of the 
current study, both PMN depletion and CXCR2 blockade 
prevented BBB breakdown during initial clinical presentation 
and relapse ( Fig. 3 and  Fig. 5 ). Furthermore, WT PMN transfer 
was suffi  cient to promote vascular compromise in sensitized 
CXCR2-defi cient mice ( Fig. 8 ). Interestingly, in certain in 
vitro systems, PMN-induced changes in endothelial barrier 
 Figure 7.  WT PMN promote neuroinfl ammation in myelin-immunized CXCR2   /   mice. BALB/c CXCR2 +/+ and CXCR2   /   mice were immunized 
with PLP 185-206 in CFA. CXCR2   /   mice were injected with 5  × 10 6 purifi ed bone marrow PMN or BMMac daily between days 10 and 14 after immuniza-
tion. Spinal cords were removed between days 13 and 15 after immunization, fi xed, and hematoxylin and eosin stained. Representative sections of three 
mice per group are shown. Bars: (left and middle) 200  μ m; (right) 50  μ m. 
 Table I.  WT PMN transfer restores EAE susceptibility 
in CXCR2   /   mice 
Incidence Mean day  
 of onset
Mean  
 peak score
WT 100% 12.2 2.2
  /  0%  – 0
WT PMN →  /  a 100% 13.5 1
WT BMMac →  /  a 0%  – 0
Data are representative of at least three independent experiments. WT,  n = 15; 
  /  ,  n = 12; WT PMN →  /  ,  n = 10; WT BMMac →  /  ,  n = 9.
 a 5  × 10 6 cells transferred i.p. daily from day 10 – 14 after immunization.
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( Fig. 1 ), raising the possibility that IL-17 amplifi es ELR + 
CXC chemokine production in EAE lesions as disease pro-
gresses. In fact, we have found that adoptive transfer of puri-
fi ed myelin-specifi c Th17, but not lineage-uncommitted, 
CD4 + T cells triggers conspicuous CXCL1 and CXCL2 tran-
scription in the CNS ( Fig. 2 B ). On the other hand, EAE in-
duction by myelin-reactive Th1 cells is more closely associated 
with CNS up-regulation of ELR    than ELR + CXC chemo-
kines (unpublished data). 
 Irrespective of the mechanism of action of PMN in EAE, 
the current study identifi es ELR + CXC chemokines and the 
CXCR2/1 receptors as novel therapeutic targets in auto-
immune diseases such as MS that might work synergistically 
with reagents that impede lymphocyte traffi  cking and/or 
function. This approach is particularly attractive, because 
Furthermore, recipients of the T cell lines were irradiated 
before adoptive transfer. If our theory is correct, Abromson-
Leemans ’ s protocol may have circumvented the requirement 
for PMN and ELR + CXC chemokines because irradiation, 
in and of itself, could trigger both immediate and long-term 
BBB disruption ( 52 ). 
 The results of our experiments dovetail nicely with re-
ports from other laboratories that the IL-23 – IL-17 axis plays a 
nonredundant role in the pathogenesis of EAE ( 53 ). Although 
Th17 cells have emerged as critical autoimmune eff ectors, 
the events linking IL-17 signaling to target organ infl amma-
tion and tissue damage are unknown. A major function of 
IL-17 is to induce production of ELR + CXC chemokines ( 54 ). 
CNS expression of ELR + CXC chemokines closely mirrors 
that of IL-17 during the relapsing-remitting course of EAE 
 Figure 8.  WT PMN induce BBB breakdown and CNS cytokine expression in myelin-immunized CXCR2   /   mice but do not affect peripheral 
CD4 + T cell responses. BALB/c CXCR2 +/+ and CXCR2   /   mice were immunized with PLP 185-206 in CFA. CXCR2   /   mice were injected with 5  × 10 6 purifi ed 
bone marrow PMN or BMMac daily between days 10 and 14 after immunization. (A) Cerebrovascular permeability was assessed by Evans blue dye ex-
travasation on day 14 after immunization. Data represent mean  ± SD. *, P  < 0.05 compared with naive mice. (B) RNA was isolated from spinal cords be-
tween days 13 and 15 after immunization and analyzed by real-time RT-PCR. Data represent fold induction compared with naive spinal cords ( n = 4 mice 
per group). *, P  < 0.03 compared with CXCR2   /   mice. n.d., not detectable. (C and D) CD4 + T cells were isolated from draining lymph nodes on day 14 
after immunization. The purifi ed T cells were cultured with naive T cell – depleted splenocytes plus or minus PLP 139-151 . Lymphoproliferative and cytokine 
responses were measured by [ 3 H]thymidine uptake (C) and ELISPOT (D) assays, respectively. The ELISPOT data shown were generated by subtracting back-
ground spots (six or fewer) that appeared in the absence of antigenic challenge. Data represent mean  ± SD. 
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Spleens were depleted of T cells by complement-mediated lysis with J1J 
(anti-Thy1.2) hybridoma supernatants and guinea pig complement (Rockland 
Immunochemicals). Purifi ed CD4 + T cells were cultured with T cell – 
depleted splenocytes at a ratio of 1:4 (5  × 10 5 cells/well in 0.2 ml of tissue 
culture media) and stimulated in vitro with 25  μ g/ml of either PLP 139-151 
(SJL) or PLP 185-206 (BALB/c) media, or 0.5  μ g/ml anti-CD3. For prolifera-
tion experiments, cells were cultured in fl at-bottom 96-well plates for 96 h. 
1  μ Ci/well [ 3 H]thymidine (GE Healthcare) was added for the last 16 h of 
culture. Incorporated radioactivity was measured using a scintillation coun-
ter (Betaplate; PerkinElmer). ELISPOT assays were performed in 96-well 
fi ltration plates (Millipore) with noncompeting antibody pairs. Cells were 
cultured (100  μ l/well at 37 ° C) with or without 50  μ g/ml of antigen for 
24 h before application of biotinylated secondary antibodies and streptavidin-
alkaline phosphatase. Plates were developed with Vector Blue (Vector Lab-
oratories), and spots were counted using an analyzer (CTL ImmunoSpot) 
with ImmunoSpot software (version 2.08; both from Cellular Technology). 
All assays were performed in triplicate. 
 BBB permeability.  Mice were injected i.v. with 2% Evans blue dye (0.01 
ml/g; Sigma-Aldrich) and perfused with PBS by the intracardiac route 2 h 
later. Spinal cord and kidney samples were homogenized in formamide 
(20 ml/g of tissue wet weight; Sigma-Aldrich), and dye was extracted over-
night. After centrifugation at 21,000  g for 30 min, supernatants were 
removed and absorbance was measured at 620 and 740 nm. Background 
 absorbance (calculated as   log OD 620 = (0.964)(  log OD 740 )   0.0357) was 
subtracted to obtain the data shown in the fi gures, as previously described 
( 55 ). Relative permeability represents the ratio of Evans blue extravasation 
(micrograms of dye per gram of tissue) from spinal cord homogenates to 
kidney homogenates. 
 Real-time RT-PCR.  RNA was isolated with TRI zol (Invitrogen) ac-
cording to the manufacturer ’ s protocol. cDNA was synthesized with a re-
verse transcription kit (QuantiTect; QIAGEN). PCR was performed using 
a single-color real-time PCR detection system (MyiQ; Bio-Rad Labora-
tories). Primers and probes were designed with Beacon Designer (Premier 
Biosoft International). Samples were amplifi ed over 40 cycles according to 
the following protocol: 15 s at 95 ° C, 1 min at 60 ° C. Target gene ex-
pression was normalized to GAPDH. The relative expression of mRNA in 
tissues from immunized mice versus naive mice was determined using the 
REST-XL software tool (version 2) ( 56 ), and data are represented as fold 
induction compared with naive controls. General trends and statistical sig-
nifi cance were similar when   -actin was used as the housekeeping gene 
(unpublished data). 
 Cell transfer experiments.  PMN ( > 97% purity) were isolated from bone 
marrow using anti – Ly6G-biotin and antibiotin microbeads (Miltenyi Bio-
tec). Enriched bone marrow macrophages (BMMac; 82 – 87% purity) were 
enriched from whole bone marrow cells by culture with 10 ng/ml M-CSF. 
After 5 d, adherent cells were harvested and isolated over a 62% Percoll gra-
dient by centrifugation for 30 min at 1,500  g . Ly6G + cells were removed 
with anti – Ly6G-biotin/antibiotin beads. Cytospins and fl ow cytometry 
were used to confi rm cellular purity (Fig. S2, available at http://www.jem
.org/cgi/content/full/jem.20072404/DC1). Recipient mice were injected 
with 5  × 10 6 PMN or BMMac i.p. 
 Statistical analysis.  Real-time RT-PCR data were analyzed by the pair-
wise fi xed reallocation randomization test with REST-XL software (version 2). 
All other data were analyzed by the Mann-Whitney test with Prism 5 soft-
ware (GraphPad Software). 
 Online supplemental material.  Fig. S1 shows the PMN depletion effi  -
ciency and specificity of the RB6 mAb on PBL subsets. Fig. S2 shows 
the purity of PMN and BMMac used for transfer into CXCR2   /   mice. 
Online supplemental material is available at http://www.jem.org/cgi/content/
full/jem.20072404/DC1. 
drugs that block PMN activation and/or adherence to the 
luminal surface of CNS vessels might be therapeutically ef-
fective without having to cross the BBB. 
 MATERIALS AND METHODS 
 Mice.  SJL and BALB/c mice were purchased from the National Cancer In-
stitute at 6 – 8 wk of age. BALB/c CXCR2   /   , CXCR2 +/   , and CXCR2 +/+ 
mice littermates (originally purchased from Jackson ImmunoResearch Labo-
ratories) were bred in our laboratory, as previously described ( 26 ). Mice 
were housed in a specifi c pathogen-free facility at the University of Roches-
ter School of Medicine and Dentistry. All experiments were approved by the 
University of Rochester Committee on Animal Resources. 
 Antibodies and reagents.  The following mAbs were purchased for fl ow 
cytometry: B220 (RA3-62), CD3 (145-2C11), CD4 (RM4-5), CD8 
(53-6.7), CD11c (HL3), Ly6C (AL-21), Ly6G (1A8), MHC class II (7-16.17; 
BD Biosciences); 7/4 (Caltag and Serotec); and CD11b (M1/70), F4/80 
(BM8), Gr-1 (RB6), and M-CSF R (AFS98; eBioscience). RB6 (Gr-1) mAbs 
were purifi ed from hybridoma supernatants on protein G columns (GE 
Healthcare). Recombinant mouse M-CSF was purchased from PeproTech. 
 Induction and assessment of EAE.  Mice were immunized subcutane-
ously over the fl anks with 100  μ g PLP 139-151 (SJL) or PLP 185-206 (BALB/c) in 
CFA containing 250  μ g  Mycobacterium tuberculosis H37RA (Difco). BALB/c 
mice were injected i.p. with 300 ng  Bordetella pertussis toxin (List Biological 
Laboratories) on days 0 and 2 after immunization. Clinical assessment of 
EAE was performed according to the following criteria: 0, no disease; 1, 
limp tail; 2, hind-limb weakness; 3, partial hind-limb paralysis; 4, complete 
paralysis of one or more limbs; and 5, moribund state. 
 CXCR2 neutralization.  Anti-CXCR2 antiserum was prepared by im-
munizing rabbits with a peptide (Met-Gly-Glu-Phe-Lys-Val-Asp-Lys-
Phe-Asn-Ile-Glu-Asp-Phe-Phe-Ser-Gly) derived from the ligand binding 
site of CXCR2 (Biosynthesis) ( 13 ). To block CXCR2 in vivo, 0.5 ml of 
anti-CXCR2 antiserum was injected i.p. every third day. NRS was used as 
a control. Anti-CXCR2 antiserum failed to induce complement-mediated 
lysis of purifi ed PMN in vitro or to deplete PMN (Ly6G + , 7/4 + , MHC 
class II    cells) after in vivo administration of 0.5 ml i.p. every third day 
(unpublished data). The antiserum stained WT but not CXCR2   /   PMN 
(unpublished data). 
 Flow cytometric analysis.  Cells were incubated with FcBlock (hybridoma 
2.4G2; American Type Culture Collection) followed by biotinylated or fl uo-
rochrome-conjugated antibodies for 10 min on ice. For secondary staining, 
cells were washed and incubated with PerCP- or allophycocyanin-conju-
gated streptavidin for an additional 10 min. Data acquisition was performed 
on a fl ow cytometer (FACSCalibur; BD Biosciences) and analyzed with 
FlowJo software (Tree Star, Inc.). 
 Histology.  Mice were perfused with 10% formalin, and vertebral columns 
were dissected and decalcifi ed with Immunocal (Decal Chemical Corpora-
tion). Cords were fi xed in 10% formalin, paraffi  n embedded, sectioned, and 
Giemsa stained. Images were captured on a microscope (Axioplan 2; Carl 
Zeiss, Inc.) with a SPOT camera and SPOT Advanced software (Diagnostic 
Instruments, Inc.). 
 CNS cell isolation.  Mice were anesthetized with avertin and perfused with 
PBS by the intracardiac route. Spinal cords were minced and digested with 
2 mg/ml of collagenase (CLS-4; Worthington Biochemical) and 1 mg/ml 
DNase I (DN25; Sigma-Aldrich) for 1 h at 37 ° C. Pooled spinal cord cells 
were layered over a discontinuous Percoll gradient, centrifuged for 25 min 
at 2,500 rpm, and collected from the 30/70% interface. 
 In vitro T cell assays.  CD4 + T cells were purifi ed from pooled lymph nodes 
and spleens using CD4 + T cell enrichment columns (Cedarlane  Laboratories). 
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